Sign up
Pharma Capital
EPIC: SCYX
Market: NASDAQ
52-week High/Low: $2.49 / $1.05
Sector: Health Care, Equipment & Services
Market Cap: $57.83M
Website: www.scynexis.com

SCYNEXIS, Inc., a drug development company, develops and commercializes anti-infectives to address unmet therapeutic needs. It is developing its lead product candidate, SCY-078, as a novel oral and intravenous drug for the treatment of various fungal infections, including serious and life-threatening invasive fungal infections. The company also develops SCY-078, which is in various Phase I...

SCYNEXIS, Inc.

www.scynexis.com

Interactive graph

col 3
col 4
col 5
col 6
View full SCYX profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.